MEDIVIR AB, Outperform, Monetizing Cold Sores to Focus On Improved Protease Inhibitors for HCV Treatment.
Medivir’s Xerese fetched $45m for the company from Meda AB for US, Canada and Mexico rights. Improved cash position would help MVIR concentrate more on its pipeline and in licensing opportunities. TMC435 (Protease Inhibitor, PhII/III, partnered with Tibotec/JNJ) could offer compelling advantage over currently approved PIs and remains the key driver MVIR. For more detail, please read our report released on 29th June on MVIR titled “Monetizing Cold Sores to Focus On Improved Protease Inhibitors for HCV Treatment” and Initiation report released on 24th June titled “Next in HCV- A Once Daily Protease Inhibitor Option”.
COMPANIES MENTIONED
MEDIVIR AB, MVIR,
MEDIVIR AB, MVIR,
